{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:49:23Z","timestamp":1792619363347,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00862-3","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:24:41Z","timestamp":1764332681000},"page":"269-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Real-World Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Hans-Peter","family":"Hartung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazem","family":"Atassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Alonso-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Seluzhytsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Smolkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Dormont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mati","family":"Lopez-Grancha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"862_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaut.2019.04.021","volume":"102","author":"Y Rodr\u00edguez","year":"2019","unstructured":"Rodr\u00edguez Y, Vatti N, Ram\u00edrez-Santana C, Chang C, Mancera-P\u00e1ez O, Gershwin ME, et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019;102:8\u201337.","journal-title":"J Autoimmun"},{"issue":"11","key":"862_CR2","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force\u2014second revision. Eur J Neurol. 2021;28(11):3556\u201383.","journal-title":"Eur J Neurol"},{"issue":"1","key":"862_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12325-020-01540-6","volume":"38","author":"JA Allen","year":"2021","unstructured":"Allen JA, Butler L, Levine T, Haudrich A. A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory demyelinating polyneuropathy. Adv Ther. 2021;38(1):316\u201328.","journal-title":"Adv Ther"},{"issue":"17 Suppl","key":"862_CR4","first-page":"S371","volume":"24","author":"M Ryan","year":"2018","unstructured":"Ryan M, Ryan SJ. Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health. Am J Manag Care. 2018;24(17 Suppl):S371\u20139.","journal-title":"Am J Manag Care"},{"key":"862_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-981-32-9636-7_21","volume":"1190","author":"S Kuwabara","year":"2019","unstructured":"Kuwabara S, Misawa S. Chronic inflammatory demyelinating polyneuropathy. Adv Exp Med Biol. 2019;1190:333\u201343.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"862_CR6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.clinph.2020.12.017","volume":"132","author":"A Al-Zuhairy","year":"2021","unstructured":"Al-Zuhairy A, Jakobsen J, Krarup C. Early axonal loss predicts long-term disability in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2021;132(4):1000\u20137.","journal-title":"Clin Neurophysiol"},{"issue":"3\u20134","key":"862_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000494291","volume":"52","author":"MC Broers","year":"2019","unstructured":"Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology. 2019;52(3\u20134):161\u201372.","journal-title":"Neuroepidemiology"},{"issue":"10","key":"862_CR8","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","volume":"268","author":"L Querol","year":"2021","unstructured":"Querol L, Crabtree M, Herepath M, Priedane E, Viejo Viejo I, Agush S, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2021;268(10):3706\u201316.","journal-title":"J Neurol"},{"issue":"9","key":"862_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","volume":"90","author":"HC Lehmann","year":"2019","unstructured":"Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;90(9):981\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"862_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/mus.21206","volume":"39","author":"YA Rajabally","year":"2009","unstructured":"Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009;39(4):432\u20138.","journal-title":"Muscle Nerve"},{"issue":"9","key":"862_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","volume":"86","author":"EK Mathey","year":"2015","unstructured":"Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973\u201385.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"862_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/mus.26315","volume":"58","author":"D Mengel","year":"2018","unstructured":"Mengel D, Fraune L, Sommer N, Stettner M, Reese JP, Dams J, et al. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. Muscle Nerve. 2018;58(5):681\u20137.","journal-title":"Muscle Nerve"},{"issue":"1","key":"862_CR13","volume":"1","author":"AL Oaklander","year":"2017","unstructured":"Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;1(1):Cd010369.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"862_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RAC Hughes","year":"2008","unstructured":"Hughes RAC, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136\u201344.","journal-title":"Lancet Neurol"},{"issue":"8","key":"862_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40263-019-00655-x","volume":"33","author":"YN Lamb","year":"2019","unstructured":"Lamb YN, Syed YY, Dhillon S. Immune globulin subcutaneous (human) 20% (Hizentra\u00ae): a review in chronic inflammatory demyelinating polyneuropathy. CNS Drugs. 2019;33(8):831\u20138.","journal-title":"CNS Drugs"},{"issue":"2","key":"862_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/jns5.12017","volume":"18","author":"JM L\u00e9ger","year":"2013","unstructured":"L\u00e9ger JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, et al. Efficacy and safety of Privigen\u00ae\u00a0in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label phase III study (the PRIMA study). J Peripher Nerv Syst. 2013;18(2):130\u201340.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"862_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/jns.12302","volume":"24","author":"ISJ Merkies","year":"2019","unstructured":"Merkies ISJ, van Schaik IN, L\u00e9ger JM, Bril V, van Geloven N, Hartung HP, et al. Efficacy and safety of IVIG in CIDP: combined data of the PRIMA and PATH studies. J Peripher Nerv Syst. 2019;24(1):48\u201355.","journal-title":"J Peripher Nerv Syst"},{"key":"862_CR18","doi-asserted-by":"publisher","first-page":"1326874","DOI":"10.3389\/fneur.2024.1326874","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Hu J, Sun C, Qiao K, Zhao Y, Liu B, et al. Insights into refractory chronic inflammatory demyelinating polyneuropathy: a comprehensive real-world study. Front Neurol. 2024;15:1326874.","journal-title":"Front Neurol"},{"issue":"10","key":"862_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16399","volume":"31","author":"YA Rajabally","year":"2024","unstructured":"Rajabally YA, Min YG, Nazeer KK, Englezou C. Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: study of a UK cohort. Eur J Neurol. 2024;31(10):e16399.","journal-title":"Eur J Neurol"},{"issue":"1","key":"862_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jnnp-2024-334165","volume":"96","author":"D Mair","year":"2025","unstructured":"Mair D, Madi H, Eftimov F, Lunn MP, Keddie S. Novel therapies in CIDP. J Neurol Neurosurg Psychiatry. 2025;96(1):38\u201346.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"862_CR21","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1007\/s00415-024-12548-1","volume":"271","author":"P Quint","year":"2024","unstructured":"Quint P, Schroeter CB, Kohle F, \u00d6zt\u00fcrk M, Meisel A, Tamburrino G, et al. Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort. J Neurol. 2024;271(9):5930\u201343.","journal-title":"J Neurol"},{"key":"862_CR22","unstructured":"Optum\u00ae Market Clarity Data [Internet]. [cited September 02, 2024]. https:\/\/www.optum.com\/content\/dam\/optum3\/optum\/en\/resources\/brochures\/market-clarity-data-product-sheet.pdf."},{"key":"862_CR23","unstructured":"Optum\u00ae Follow patient journeys with Market Clarity\u2122 integrated real-world data [Internet]. [cited September 02, 2024]. https:\/\/www.optum.com\/content\/dam\/o4-dam\/resources\/pdfs\/sell-sheets\/mc-sell-sheet.pdf."},{"issue":"3","key":"862_CR24","first-page":"127","volume":"12","author":"JT Guptill","year":"2019","unstructured":"Guptill JT, Runken MC, Eaddy M, Lunacsek O, Fuldeore RM. Treatment patterns and costs of chronic inflammatory demyelinating polyneuropathy: a claims database analysis. Am Health Drug Benefits. 2019;12(3):127\u201335.","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"862_CR25","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.1016\/j.jval.2024.03.1778","volume":"27","author":"C Arvin-Berod","year":"2024","unstructured":"Arvin-Berod C, Blein C, Guptill JG, Gelinas D, Barrera-Sierra SBS, Ulla H, et al. RWD124 Validation of treatment patterns in adults with chronic inflammatory demyelinating polyneuropathy in the United States using administrative claims datasets. Value Health. 2024;27(6):S381\u20132.","journal-title":"Value Health"},{"issue":"10","key":"862_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206205","volume":"13","author":"V Divino","year":"2018","unstructured":"Divino V, Mallick R, DeKoven M, Krishnarajah G. The economic burden of CIDP in the United States: a case\u2013control study. PLoS One. 2018;13(10):e0206205.","journal-title":"PLoS One"},{"key":"862_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117098","volume":"418","author":"J Godil","year":"2020","unstructured":"Godil J, Barrett MJ, Ensrud E, Chahin N, Karam C. Refractory CIDP: clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci. 2020;418:117098.","journal-title":"J Neurol Sci"},{"issue":"2","key":"862_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","volume":"17","author":"D Cocito","year":"2010","unstructured":"Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17(2):289\u201394.","journal-title":"Eur J Neurol"},{"issue":"2","key":"862_CR29","first-page":"Cd001797","volume":"2","author":"SR Bus","year":"2024","unstructured":"Bus SR, de Haan RJ, Vermeulen M, van Schaik IN, Eftimov F. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2024;2(2):Cd001797.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"862_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awab422","volume":"145","author":"DR Cornblath","year":"2022","unstructured":"Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, et al. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022;145(3):887\u201396.","journal-title":"Brain"},{"issue":"1","key":"862_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16575","volume":"32","author":"YG Min","year":"2025","unstructured":"Min YG, Jeon J, Kim SM, Hong YH, Englezou C, Sung JJ, et al. Determinants of long-term disability in chronic inflammatory demyelinating polyradiculoneuropathy: a multicenter Korea\/UK study of 144 patients. Eur J Neurol. 2025;32(1):e16575.","journal-title":"Eur J Neurol"},{"key":"862_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/jnnp-2018-318714","volume":"90","author":"PE Doneddu","year":"2019","unstructured":"Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, Filosto M, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019;90:125\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"862_CR33","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jval.2024.03.319","volume":"27","author":"JG Guptill","year":"2024","unstructured":"Guptill JG, Blein C, Arvin-Berod C, Gelinas D, Barrera-Sierra SBS, Ulla H, et al. EE18 Burden of illness for adults with chronic inflammatory demyelinating polyneuropathy in the United States. Value Health. 2024;27(6):S60.","journal-title":"Value Health"},{"issue":"4","key":"862_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/mus.25271","volume":"55","author":"A Kaplan","year":"2017","unstructured":"Kaplan A, Brannagan III TH. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2017;55(4):476\u201382.","journal-title":"Muscle Nerve"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00862-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00862-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00862-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:52:01Z","timestamp":1768398721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00862-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00862-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hans-Peter Hartung has received consulting fees from Sanofi and Octapharma, and served on steering\/data monitoring committees and scientific adboard for Biogen, BMS Celgene, Boehringer Ingelheim, GeNeuro, Merck, Novartis, Octapharma, Roche, and TG Therapeutics. Hans Peter Hartung is an Editorial Board member of Neurology and Therapy. Hans Peter Hartung was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Nazem Atassi, Miguel Alonso-Alonso, Manuel Nunez, Alex Seluzhytsky, Ekaterina Smolkina, Flavio Dormont, Mati Lopez-Grancha, and Omar Saeed are employees of Sanofi and may hold stocks or stock options in the company. Marvin Nguyen is an employee of Daiichi Sankyo. Marvin was employed at Sanofi at the time of this study\u2019s conduct. Richard Lewis received consulting fees for Alexion, Amgen, Annexon, Argenx, Avilar, BioCryst, CSL Behring, Dianthus, Grifols, Johnson & Johnson, Immunovant, Nervosave, Nuvig, Sanofi, Seismic, Takeda, TG Therapeutics; served on data safety monitoring board\/advisory board for Boehringer Ingelheim, Intellia Therapeutics, Inc., and Cartesian Therapeutics, Inc.; a medical advisory board member for the GBS-CIDP Foundation International and the Myasthenia Gravis Foundation of America (MGFA); and a member of speaker\u2019s bureau for Medscape, PeerView and PeerVoice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"An ethics review was not required as the study utilized a de-identified claims database. Sanofi was granted access to the dataset through a licensing agreement with Optum\n                      \u00ae\n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}